Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED).

A. U. Buzdar, G. R. Blumenschein, T. L. Smith, C. K. Tashima, G. N. Hortobagyi, H. Y. Yap, J. U. Gutterman, Evan M Hersh, E. A. Gehan

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

A combination of 5-fluorouracil, Adriamycin, cyclophosphamide, and BCG (FAC-BCG) was evaluated as adjuvant treatment in breast cancer patients following surgical excision and/or radiation of first site of recurrent disease. In a group of 68 patients treated with FAC-BCG, the estimated proportion remaining free of disease at 2 years from first recurrence was 69%, compared to 24% in 60 historical control patients (P less than 0.01). Estimated 2-year survival rate from first recurrence was 85% for the FAC-BCG patients and 78% for the controls (P = 0.07). This regimen has significantly prolonged the disease-free interval from the first recurrence, but additional follow-up is needed to determine its effect on long-term survival.

Original languageEnglish (US)
Pages (from-to)27-40
Number of pages14
JournalJournal of Surgical Oncology
Volume12
Issue number1
StatePublished - 1979
Externally publishedYes

Fingerprint

Mycobacterium bovis
Fluorouracil
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Recurrence
Therapeutics
Survival Rate
Radiation
Survival

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Buzdar, A. U., Blumenschein, G. R., Smith, T. L., Tashima, C. K., Hortobagyi, G. N., Yap, H. Y., ... Gehan, E. A. (1979). Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). Journal of Surgical Oncology, 12(1), 27-40.

Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). / Buzdar, A. U.; Blumenschein, G. R.; Smith, T. L.; Tashima, C. K.; Hortobagyi, G. N.; Yap, H. Y.; Gutterman, J. U.; Hersh, Evan M; Gehan, E. A.

In: Journal of Surgical Oncology, Vol. 12, No. 1, 1979, p. 27-40.

Research output: Contribution to journalArticle

Buzdar, AU, Blumenschein, GR, Smith, TL, Tashima, CK, Hortobagyi, GN, Yap, HY, Gutterman, JU, Hersh, EM & Gehan, EA 1979, 'Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED).', Journal of Surgical Oncology, vol. 12, no. 1, pp. 27-40.
Buzdar AU, Blumenschein GR, Smith TL, Tashima CK, Hortobagyi GN, Yap HY et al. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). Journal of Surgical Oncology. 1979;12(1):27-40.
Buzdar, A. U. ; Blumenschein, G. R. ; Smith, T. L. ; Tashima, C. K. ; Hortobagyi, G. N. ; Yap, H. Y. ; Gutterman, J. U. ; Hersh, Evan M ; Gehan, E. A. / Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). In: Journal of Surgical Oncology. 1979 ; Vol. 12, No. 1. pp. 27-40.
@article{9bedfd423e2f4fe4a0fe013253addd93,
title = "Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED).",
abstract = "A combination of 5-fluorouracil, Adriamycin, cyclophosphamide, and BCG (FAC-BCG) was evaluated as adjuvant treatment in breast cancer patients following surgical excision and/or radiation of first site of recurrent disease. In a group of 68 patients treated with FAC-BCG, the estimated proportion remaining free of disease at 2 years from first recurrence was 69{\%}, compared to 24{\%} in 60 historical control patients (P less than 0.01). Estimated 2-year survival rate from first recurrence was 85{\%} for the FAC-BCG patients and 78{\%} for the controls (P = 0.07). This regimen has significantly prolonged the disease-free interval from the first recurrence, but additional follow-up is needed to determine its effect on long-term survival.",
author = "Buzdar, {A. U.} and Blumenschein, {G. R.} and Smith, {T. L.} and Tashima, {C. K.} and Hortobagyi, {G. N.} and Yap, {H. Y.} and Gutterman, {J. U.} and Hersh, {Evan M} and Gehan, {E. A.}",
year = "1979",
language = "English (US)",
volume = "12",
pages = "27--40",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED).

AU - Buzdar, A. U.

AU - Blumenschein, G. R.

AU - Smith, T. L.

AU - Tashima, C. K.

AU - Hortobagyi, G. N.

AU - Yap, H. Y.

AU - Gutterman, J. U.

AU - Hersh, Evan M

AU - Gehan, E. A.

PY - 1979

Y1 - 1979

N2 - A combination of 5-fluorouracil, Adriamycin, cyclophosphamide, and BCG (FAC-BCG) was evaluated as adjuvant treatment in breast cancer patients following surgical excision and/or radiation of first site of recurrent disease. In a group of 68 patients treated with FAC-BCG, the estimated proportion remaining free of disease at 2 years from first recurrence was 69%, compared to 24% in 60 historical control patients (P less than 0.01). Estimated 2-year survival rate from first recurrence was 85% for the FAC-BCG patients and 78% for the controls (P = 0.07). This regimen has significantly prolonged the disease-free interval from the first recurrence, but additional follow-up is needed to determine its effect on long-term survival.

AB - A combination of 5-fluorouracil, Adriamycin, cyclophosphamide, and BCG (FAC-BCG) was evaluated as adjuvant treatment in breast cancer patients following surgical excision and/or radiation of first site of recurrent disease. In a group of 68 patients treated with FAC-BCG, the estimated proportion remaining free of disease at 2 years from first recurrence was 69%, compared to 24% in 60 historical control patients (P less than 0.01). Estimated 2-year survival rate from first recurrence was 85% for the FAC-BCG patients and 78% for the controls (P = 0.07). This regimen has significantly prolonged the disease-free interval from the first recurrence, but additional follow-up is needed to determine its effect on long-term survival.

UR - http://www.scopus.com/inward/record.url?scp=0018370222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018370222&partnerID=8YFLogxK

M3 - Article

C2 - 480951

AN - SCOPUS:0018370222

VL - 12

SP - 27

EP - 40

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 1

ER -